# PE-22-28

Source: https://aminodesk.com/library/pe-22-28
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

PE-22-28 is a seven-amino-acid peptide sold as a mood and focus compound. It was designed by French researchers as an improved version of a natural peptide called spadin. All of the evidence is in rodents.

- **Legal lane:** not FDA-approved. Sold as a research chemical.
- **Evidence grade:** D
- **Form:** nasal spray or injection as sold
- **Established human dose:** none

## What it is

A shortened analog of spadin. It blocks a potassium channel in nerve cells called TREK-1, which makes those cells more responsive. In laboratory tests it blocked the channel far more strongly than spadin and lasted longer in the body.

## What the evidence shows

The 2017 paper that introduced it reported antidepressant-like behavior in mice and signs of new nerve cell growth. The authors called it a promising alternative to spadin for treating depression.

No human trial of PE-22-28 or of spadin has been completed or registered, according to a clinical summary last updated in September 2026.

## Legal status

- Not FDA-approved for any use.
- Not one of the six peptides in the October 2026 compounding policy.
- What is sold online is a research chemical.

## Reported dosing

**We do not publish a protocol for this compound.**

No dose has been established in people.

## Safety

- The channel it blocks is also found in the heart, pancreas and gut. The effects of blocking it throughout the body are uncharacterized.
- Depression is treatable with therapies that have been tested. An untested research chemical is not a safe substitute, and stopping a prescribed antidepressant to try one is risky.
- Products sold as research chemicals have no verified contents or sterility.

## Common questions

### Has PE-22-28 been tested in humans?

No. The evidence is from rodents.

### What does PE-22-28 do?

It blocks the TREK-1 potassium channel, which produced antidepressant-like effects in mice.

### Is PE-22-28 legal?

It is not FDA-approved and is sold only as a research chemical.

## Sources

- [Djillani et al., 2017: shortened spadin analogs, TREK-1 inhibition and antidepressant activity (PubMed)](https://pubmed.ncbi.nlm.nih.gov/28955242/)
- [Superpower: PE-22-28 research stage and status](https://superpower.com/guides/peptide-science/pe-22-28)
- [Outliyr: PE-22-28 assessment and off-target concerns](https://outliyr.com/health-optimization-index/pe-22-28)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
